Blood Reviews
Volume 22, Issue 6 , Pages 303-309, November 2008

Frontline treatment of multiple myeloma in elderly patients

  • Philippe Moreau

      Affiliations

    • Hematology Department, University Hospital Hôtel-Dieu, Place A.Ricordeau, 44093 Nantes cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 240083271; fax: +33 240083250.
    • ,
  • Cyrille Hulin

      Affiliations

    • Hematology Department, University Hospital Brabois, Route de Neufchâteau, 54000 Nancy, France
    • Tel.: +33 383153599; fax: +33 383153558.
    • ,
  • Thierry Facon

      Affiliations

    • Hematology Department, University Hospital Huriez, Place de Verdun, 59037 Lille cedex, France
    • Tel.: +33 320444290; fax: +33 320444094.

published online 12 June 2008.

Summary 

Until 2007, frontline chemotherapy with melphalan and prednisone (MP) was considered as the standard of care in the treatment of elderly patients with multiple myeloma (MM). Recently, several prospective randomized studies comparing MP with the same combination plus new agents such as thalidomide (MPT) or bortezomib (MPV) clearly showed that MPT and MPV were superior to MP in terms of progression-free and overall survival. Melphalan–prednisone–lenalidomide (MPR) is currently compared to MP in one prospective trial and will also probably be superior to MP. Lenalidomide plus low-dose dexamethasone is a promising combination. Thus, at least four highly active new treatment options are now available to treat elderly patients with MM. The goal of future trials will be to determine the best treatment strategy in this group of patients.

Keywords: Multiple myeloma, Elderly patients, Thalidomide, Bortezomib, Lenalidomide

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0268-960X(08)00037-4

doi:10.1016/j.blre.2008.04.002

Blood Reviews
Volume 22, Issue 6 , Pages 303-309, November 2008

Article Tools